Skip to main content


Healthcare costs

12-17-2020 | Canagliflozin | News

Model demonstrates cost-effectiveness of canagliflozin in type 2 diabetes

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

06-23-2018 | Medication adherence | Article

Cost-related medication non-adherence among US adults with diabetes

Kang H et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.06.016

06-16-2018 | Medications | Review | Article

Availability and affordability of essential medicines: Implications for global diabetes treatment

Beran D et al. Curr Diab Rep 2018; 18: 48. doi: 10.1007/s11892-018-1019-z

05-09-2018 | Liraglutide (T2DM) | Article

Real-world clinical effectiveness and cost savings of liraglutide versus sitagliptin in treating type 2 diabetes for 1 and 2 years

Li Q et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0432-2

04-30-2018 | Insulin degludec | Article

DEVOTE 5: Evaluating the short-term cost-utility of insulin degludec versus insulin glargine U100 in basal–bolus regimens for type 2 diabetes in the UK

Pollock RF et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0430-4

04-19-2018 | Type 2 diabetes | Article

Treatment intensification in type 2 diabetes: A real-world study of 2-OAD regimens, GLP-1 RAs, or basal insulin

Blonde L et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0429-x

04-11-2018 | Insulin | Article

Adherence to basal insulin therapy among people with type 2 diabetes: A retrospective cohort study of costs and patient outcomes

Perez-Nieves M et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0421-5

02-21-2018 | Insulin aspart | Review | Article

15 years of experience with biphasic insulin aspart 30 in type 2 diabetes

Liebl A et al. Drugs R D 2018; 18: 27–39. doi: 10.1007/s40268-018-0228-x

02-06-2018 | Healthcare costs | Article

Cost-effectiveness analysis of canagliflozin 300 mg versus dapagliflozin 10 mg added to metformin in patients with type 2 diabetes in the United States

Neslusan C et al. Diabetes Ther 2018; Advance online publication. doi: 10.1007/s13300-018-0371-y

09-06-2017 | Healthcare costs | View from the clinic | Article

The rising cost of medication: Groceries or insulin?

Advisory Board member and Family Physician, Allison Petznick, highlights the impact of rising medication costs on one of her patients, and provides practical suggestions for US physicians to help those struggling to manage the everyday costs of type 2 diabetes.

04-15-2005 | Hypertension | Article

Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes

Clarke PM et al. Diabetologia 2005; 48: 868–877. doi: 10.1007/s00125-005-1717-3

03-01-2001 | Metformin | Article

Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type 2 diabetes

Clarke P et al. Diabetologia 2001; 44: 298–304. doi: 10.1007/s001250051617

Image Credits